|
Mambetova A.M., Gaturaeva Sh.N., Semenova I.L.
Participation of fibroblast factor 23 in the development of acute myocardial infarction in patients with chronic kidney disease
|
№1 / 2023
|
|
D.V. Artemov
The use of a complex of ferric oxyhydroxide, sucrose and starch (Velforo 500) in patients on programmed hemodialysis in the routine practice of an outpatient dialysis center: results of a prospective randomized trial
|
№4 / 2021
|
|
A.M. Esayan, A.R. Rind
The role of patient’s adherence in the treatment of hyperphosphatemia in chronic kidney disease
|
№2 / 2020
|
|
E.A. Gorelova, N.N. Chernysheva, O.N. Kotenko, E.V. Shutov
Contemporary opportunities for using phosphate binders in dialysis patients
|
№1 / 2017
|
|
V.M. Ermolenko, N.N. Filatova
New iron-containing phosphate-binding agents for the correction of hyperphosphatemia in patients with chronic kidney disease
|
№3-4 / 2016
|
|
A.Yu. Zemchenkov 1, 2, R.P. Gerasimchuk 1, K.A. Vishnevskii 1, G.A. Zemchenkov 1
Hyperphosphatemia in patients with chronic kidney disease in hemodyalisis: risks and opportunities of correction
|
№4 / 2013
|
|
Milovanova L.Yu., Milovanov Y.S., Dobrosmislov I.A., Moiseev S.V.
Perspectives of sevelamer in hyperphosphatemia treatment in patients with chronic kidney disease stage III–V
|
№5-6 / 2012
|
Русский
